文献速递急性肾损伤血液净化与透析水电解质与酸碱

肾脏替代治疗期间低磷血症与无呼吸机天数:STARRT-AKI试验事后分析

Hypophosphatemia During Kidney Replacement Therapy and Ventilator-Free Days: A Post Hoc Analysis of the STARRT-AKI Trial.
PubMed 文献 · Am J Kidney Dis · 2026-02-27

该研究为STARRT-AKI试验的事后观察性分析,纳入1942例接受肾脏替代治疗(KRT)的危重症患者,其中634例(32.6%)发生低磷血症(<0.7 mmol/L),192例(9.9%)发生重度低磷血症(<0.5 mmol/L)。调整分析显示,低磷血症和重度低磷血症均与28天无呼吸机天数(VFD)减少独立相关,但与90天死亡率或KRT依赖无关。

要点

  • 接受KRT的危重症患者中低磷血症常见,发生率达32.6%。
  • 低磷血症与28天无呼吸机天数减少独立相关。
  • 低磷血症与90天死亡率或KRT依赖无显著关联。

核心结论

  • KRT期间新发低磷血症与28天无呼吸机天数减少独立相关。

研究设计与样本

  • STARRT-AKI试验的事后观察性研究,纳入1942例接受KRT的危重症患者。

主要发现

  • 634例(32.6%)发生低磷血症,192例(9.9%)发生重度低磷血症。
  • 与低磷血症独立相关的因素包括女性、较低体重、KRT开始时较低血磷、初始CKRT及加速KRT启动随机分组。
  • 低磷血症和重度低磷血症与28天VFD减少相关(β=0.91 [95%CI 0.87-0.95] 和 β=0.87 [95%CI 0.82-0.93],均P<0.001)。
  • 配对win-ratio分析显示,低磷血症和重度低磷血症患者28天生存且无呼吸机天数复合结局的获胜几率分别低27%和25%。
  • 低磷血症与90天死亡率或KRT依赖无关联。

关键数值与推荐

  • 低磷血症定义为<0.7 mmol/L,重度低磷血症定义为<0.5 mmol/L。
  • 纳入标准包括KRT开始时血清磷≥0.5 mmol/L且KRT期间至少一次血磷测量。

临床怎么用

  • 对接受KRT的危重症患者应监测血磷,尤其女性、低体重、初始CKRT及加速启动KRT者。
  • 低磷血症可能提示呼吸功能恢复延迟风险,需关注呼吸机脱机进程。

局限性

  • 存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Critically ill patients receiving kidney replacement therapy (KRT), especially continuous KRT (CKRT), have a high risk of hypophosphatemia due to extracorporeal losses, which may contribute to muscle weakness and prolonged respiratory failure. This study evaluated the relationship between incident hypophosphatemia and respiratory function in these patients. STUDY DESIGN: Post hoc observational study of STARRT-AKI Trial participants. SETTING & PARTICIPANTS: Eligible trial participants (1) received CKRT >24 hours or intermittent hemodialysis (IHD) or sustained low-efficiency dialysis (SLED) for >1 session, (2) had a serum phosphate level ≥ 0.5 mmol/L on the day of KRT initiation, and (3) had ≥1 serum phosphate measurement during KRT. EXPOSURE: Hypophosphatemia (<0.7 mmol/L) and severe hypophosphatemia (<0.5 mmol/L) during KRT. OUTCOME: Primary outcome was ventilator-free days (VFD) at 28 days of follow-up. Secondary outcomes included mortality and KRT dependence at 90 days. ANALYTICAL APPROACH: A truncated hurdle model was fit to describe clinical characteristics associated with hypophosphatemia. Adjusted analyses of VFD used an inverse probability weighted zero-inflated negative binomial model and a win-ratio analysis. Secondary outcomes were assessed with logistic regression. RESULTS: Of 1,942 trial participants, 634 patients (32.6%) developed hypophosphatemia, and 192 patients (9.9%) developed severe hypophosphatemia. Clinical factors independently associated with incident hypophosphatemia during KRT were female sex, lower body weight, lower serum phosphate levels at KRT initiation, CKRT as the initial KRT modality, and randomization to accelerated KRT initiation. Incident hypophosphatemia and severe hypophosphatemia were associated with fewer VFD at 28 days (β, 0.91 [95% CI, 0.87-0.95] and β, 0.87 [95% CI, 0.82-0.93], respectively; P < 0.001 for both). By win-ratio for any random pair of patients, those with incident hypophosphatemia and severe hypophosphatemia had a 27% and 25% lower likelihood of combined 28-day survival and fewer days on the ventilator, respectively. There was no association between hypophosphatemia and 90-day mortality or KRT dependence. LIMITATIONS: Selection bias and unmeasured confounding. CONCLUSIONS: Incident hypophosphatemia during KRT was independently associated with fewer VFD at 28 days.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Neyra JA, Thompson Bastin M, Ghamarian E, et al. Hypophosphatemia During Kidney Replacement Therapy and Ventilator-Free Days: A Post Hoc Analysis of the STARRT-AKI Trial. Am J Kidney Dis. 2026. PMID: 41763519. doi:10.1053/j.ajkd.2025.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。